News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
549,182 Results
Type
Article (13703)
Company Profile (160)
Press Release (535317)
Multimedia
Podcasts (11)
Webinars (9)
Section
Business (179400)
Career Advice (568)
Deals (27407)
Drug Delivery (45)
Drug Development (61608)
Employer Resources (44)
FDA (11966)
Job Trends (9872)
News (263281)
Policy (21758)
Tag
2025 Best Places to Work (1)
2026 Best Places to Work (1)
2027 BioCapital Elite (1)
2027 BioCapital Standard (2)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (9)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (3)
2027 Genetown Premier (1)
2027 Genetown Standard (6)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (4)
40 Under 40 (1)
Academia (1013)
Accelerated approval (47)
ADA (31)
Adcomms (15)
Allergies (128)
Alliances (37166)
ALS (148)
Alzheimer's disease (1181)
Antibody-drug conjugate (ADC) (451)
Approvals (12711)
Artificial intelligence (559)
ASCO (237)
Autoimmune disease (288)
Automation (60)
Bankruptcy (276)
Belgium (21)
Best Places to Work (8178)
BIO (47)
Biologics (61)
BIOSECURE Act (2)
Biosimilars (153)
BioSpace Insights (58)
Biotechnology (95)
Bispecific (32)
Bladder cancer (208)
Brain cancer (69)
Breast cancer (742)
Cancer (5544)
Cardiovascular disease (350)
Career advice (479)
Career pathing (7)
CAR-T (259)
CDC (16)
CDMO (61)
Celiac Disease (5)
Cell therapy (709)
Cervical cancer (44)
Clinical research (56747)
Collaboration (1705)
Commercialization (35)
Company closure (1)
Compensation (1625)
Complete response letters (46)
COVID-19 (1194)
CRISPR (88)
CRO (2)
C-suite (994)
Cystic fibrosis (105)
Data (7999)
Decentralized trials (1)
Denatured (8)
Depression (130)
Dermatology (122)
Diabetes (496)
Diagnostics (5407)
Digital health (55)
Diversity (4)
Diversity, equity & inclusion (14)
Drug discovery (236)
Drug pricing (27)
Drug shortages (5)
Duchenne muscular dystrophy (233)
Earnings (78129)
Editorial (17)
Employer branding (5)
Employer resources (45)
ESMO (305)
Events (96388)
Executive appointments (855)
Eye disease (7)
FDA (15657)
Fibrodysplasia Ossificans Progressiva (13)
Fragile X (1)
Friedreich's ataxia (20)
Frontotemporal dementia (27)
Funding (1282)
Gene editing (171)
Generative AI (33)
Gene therapy (478)
GLP-1 (488)
Government (1645)
Grass and pollen (2)
Guidances (344)
Healthcare (11997)
Hematology (147)
HIV (71)
Huntington's disease (39)
Idiopathic pulmonary fibrosis (9)
IgA nephropathy (107)
Immunology and inflammation (154)
Immuno-oncology (98)
Indications (215)
Infectious disease (1461)
Inflammatory bowel disease (165)
Inflation Reduction Act (5)
Influenza (112)
Intellectual property (293)
Interviews (91)
IPO (13139)
IRA (4)
Job creations (2104)
Job search strategy (407)
JPM (15)
Kidney cancer (23)
Kidney disease (111)
Labor market (6)
Layoffs (99)
Leadership (12)
Legal (5626)
Licensing (61)
Liver cancer (82)
Longevity (35)
Lung cancer (765)
Lung diease (14)
Lymphoma (397)
Machine learning (47)
Management (17)
Manufacturing (889)
Marketing (29)
MASH (143)
Medical affairs (3)
Medical device (10569)
Medtech (10804)
Mergers & acquisitions (15506)
Metabolic disorders (1012)
mRNA (111)
Multiple sclerosis (145)
Multispecific (4)
NASH (9)
Netherlands (12)
Neurodegenerative disease (306)
Neuropsychiatric disorders (64)
Neuroscience (2376)
Neurotech (2)
NextGen: Class of 2026 (3823)
Non-profit (1550)
Now hiring (3)
Obesity (340)
Opinion (108)
Ovarian cancer (220)
Pain (232)
Pancreatic cancer (332)
Parkinson's disease (269)
Partnered (28)
Patents (574)
Patient advocacy (4)
Patient recruitment (695)
Patient selection (63)
Peanut (41)
People (44535)
Peptides (21)
Pharmaceutical (40)
Pharmacy benefit managers (13)
Phase 1 (17723)
Phase 2 (25168)
Phase 3 (18126)
Pipeline (10394)
Policy (73)
Postmarket research (1871)
Preclinical (7263)
Press Release (40)
Prostate cancer (286)
Psychedelics (32)
Radiopharmaceuticals (275)
Rare diseases (824)
Real estate (3543)
Recruiting (19)
Regenerative medicine (16)
Regulatory (19174)
Reports (29)
Research institute (1085)
Resumes & cover letters (91)
Rett syndrome (47)
RNA editing (11)
RSV (57)
Schizophrenia (140)
Series A (223)
Series B (153)
Service/supplier (6)
Sickle cell disease (76)
Special edition (1)
Spinal muscular atrophy (109)
Sponsored (27)
Startups (2244)
State (2)
Stem cells (5)
Stomach cancer (7)
Substance use disorders (16)
Supply chain (79)
Switzerland (3)
Tariffs (8)
Tax incentives (1)
The Weekly (3)
Vaccines (542)
Venture capital (36)
Weight loss (146)
Wet AMD (4)
Women's health (122)
Worklife (2)
Date
Last 7 days (582)
Last 30 days (2008)
Last 365 days (22918)
2026 (19146)
2025 (22655)
2024 (26669)
2023 (30439)
2022 (38632)
2021 (41406)
2020 (38293)
2019 (28829)
2018 (21639)
2017 (21898)
2016 (20912)
2015 (27222)
2014 (23640)
2013 (19841)
2012 (21995)
2011 (22330)
2010 (21857)
Location
Africa (329)
Alabama (91)
Alaska (5)
Arizona (360)
Arkansas (12)
Asia (23531)
Australia (3248)
California (14083)
Canada (3688)
China (960)
Colorado (602)
Connecticut (524)
Delaware (362)
Europe (41206)
Florida (2114)
Georgia (437)
Hawaii (3)
Idaho (51)
Illinois (952)
India (82)
Indiana (439)
Iowa (24)
Japan (549)
Kansas (115)
Kentucky (37)
Louisiana (40)
Maine (40)
Maryland (1499)
Massachusetts (9301)
Michigan (342)
Minnesota (697)
Mississippi (5)
Missouri (107)
Montana (23)
Nebraska (16)
Nevada (143)
New Hampshire (75)
New Jersey (3390)
New Mexico (24)
New York (3378)
North Carolina (1579)
North Dakota (6)
Northern California (7149)
Ohio (355)
Oklahoma (21)
Oregon (24)
Pennsylvania (2637)
Puerto Rico (27)
Rhode Island (37)
South America (538)
South Carolina (84)
South Dakota (1)
Southern California (5829)
Tennessee (172)
Texas (2294)
United States (46799)
Utah (429)
Vermont (2)
Virginia (243)
Washington D.C. (49)
Washington State (1071)
West Virginia (1)
Wisconsin (115)
Wyoming (5)
549,182 Results for "standard bariatrics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia
October 15, 2026
·
6 min read
Press Releases
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
October 6, 2026
·
7 min read
Metabolic disorders
Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia
With a Phase 3 trial showing a reduction of serious and severe hypoglycemic episodes in patients who have undergone weight loss surgery, Amylyx Pharmaceuticals plans to file for approval this year. If granted market entry, avexitide could hit peak sales of $1.7 billion worldwide, analysts estimate.
August 18, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
August 18, 2026
·
10 min read
Lymphoma
AbbVie, Genmab’s Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3
AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse large B cell lymphoma—potentially setting up a battle with Roche’s Polivy.
October 6, 2026
·
3 min read
·
Tristan Manalac
Weight loss
Lilly’s triple agonist shows bariatric surgery–like weight loss results
Lilly met analysts’ sky-high expectations with 28.3% weight loss over 80 weeks for the triple hormone receptor agonist retatrutide in a highly anticipated readout on Thursday.
May 21, 2026
·
3 min read
·
Annalee Armstrong
Press Releases
Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026
August 18, 2026
·
1 min read
Press Releases
Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026
June 15, 2026
·
3 min read
Press Releases
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
October 5, 2026
·
6 min read
Press Releases
Standard BioTools Provides Update on Sale of Mass Cytometry Business
September 30, 2026
·
11 min read
1 of 54,919
Next